Next Article in Journal
The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19
Next Article in Special Issue
Biological Evaluation of Azetidine-2-One Derivatives of Ferulic Acid as Promising Anti-Inflammatory Agents
Previous Article in Journal
Continuous Improvement Process in the Development of a Low-Cost Rotational Rheometer
Previous Article in Special Issue
Synthesis and Characterization of New Fluoro/Trifluoromethyl-Substituted Acylthiourea Derivatives with Promising Activity against Planktonic and Biofilm-Embedded Microbial Cells
Open AccessArticle

The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLC—A Matter as Actual Now as in the Past

Clinic of Oncology, Elias University Emergency Hospital, 011461 Bucharest, Romania
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
Clinic of General Surgery, Elias University Emergency Hospital, 11468 Bucharest, Romania
Cardiology Department, Elias University Emergency Hospital, 011461 Bucharest, Romania
Pneumology Clinic, Elias University Emergency Hospital, 011461 Bucharest, Romania
Thoracic Surgery Clinic, Marius Nasta National Institute of Pneumology, 050152 Bucharest, Romania
Clinic of General Surgery, Agrippa Ionescu Emergency Hospital, 011365 Bucharest, Romania
Author to whom correspondence should be addressed.
Processes 2020, 8(8), 936;
Received: 19 July 2020 / Revised: 30 July 2020 / Accepted: 31 July 2020 / Published: 4 August 2020
(This article belongs to the Special Issue Pharmaceutical Development and Bioavailability Analysis)
Lung cancer, as the leading cause of death in oncology is one of the most challenging diseases nowadays. Even after the implementation of checkpoint inhibitors and targeted therapy as a standard of therapy for metastatic disease, the chemotherapy backbone remains essential in the treatment of these patients. This study aimed to evaluate how administration particularities in chemotherapy and toxicity management can influence the outcome. We conducted a retrospective single-institution study, at Elias University Emergency Hospital, Bucharest, Romania, between 2014 and 2018, in a heterogeneous patient population with metastatic non-small cell lung cancer that received combination chemotherapy. The inclusion criteria for this trial were—histological proof of non-small cell lung cancer (NSCLC), stage IV disease, ECOG (Eastern Cooperative Oncology Group) performance status of a maximum of two, treatment with cytotoxic chemotherapy for at least four courses (patients with fewer courses were excluded). All patients received combination chemotherapy. The main focus was on the effect of dose reduction and treatment delay on overall survival and progression-free survival. A total of 129 patients were enrolled. The response rate in the studied population was 69% and 62.8% had no toxicity greater than grade 2. Chemotherapy regimens used had the following distribution—paclitaxel + carboplatin 41.9%, paclitaxel + carboplatin + bevacizumab 12.4%, pemetrexed + carboplatin 12.4%, gemcitabine + carboplatin 26.4% and other regimens 7%. Mean PFS (Progression Free Survival) was 9.1 months and the mean OS (Overall Survival) was 14 months. OS was not significantly different in the treatment delay group versus the no delay one, p < 0.25 but dose- reduction significantly impacted OS, p < 0.03. Administration particularities, like febrile neutropenia prophylaxis, treatment of chemotherapy-related anemia, respecting the details of chemostability and preparation rules and emesis prophylaxis, were considered reasons for the good outcome. Details regarding cytotoxic chemotherapy administration remain of paramount importance for a good outcome and the benefit for survival they convey is crucial. Sometimes the benefit the patient derives from these details is comparable to the one newer therapies convey. View Full-Text
Keywords: dose intensity; administration; chemotherapy dose intensity; administration; chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Nitipir, C.; Orlov-Slavu, C.; Olaru, M.; Parosanu, A.; Popa, A.-M.; Iaciu, C.; Popescu, B.C.; Barbu, M.A.; Pirlog, C.; Calu, V.; Popescu, A.C.; Bumbacea, D.; Paleru, C.; Slavu, I.; Alecu, L. The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLC—A Matter as Actual Now as in the Past. Processes 2020, 8, 936.

AMA Style

Nitipir C, Orlov-Slavu C, Olaru M, Parosanu A, Popa A-M, Iaciu C, Popescu BC, Barbu MA, Pirlog C, Calu V, Popescu AC, Bumbacea D, Paleru C, Slavu I, Alecu L. The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLC—A Matter as Actual Now as in the Past. Processes. 2020; 8(8):936.

Chicago/Turabian Style

Nitipir, Cornelia; Orlov-Slavu, Cristina; Olaru, Mihaela; Parosanu, Andreea; Popa, Ana-Maria; Iaciu, Cristian; Popescu, Bogdan C.; Barbu, Maria A.; Pirlog, Cristina; Calu, Valentin; Popescu, Andreea C.; Bumbacea, Dragos; Paleru, Cristian; Slavu, Iulian; Alecu, Lucian. 2020. "The Importance of Dose Intensity When Administering Cytotoxic Chemotherapy in NSCLC—A Matter as Actual Now as in the Past" Processes 8, no. 8: 936.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop